Cargando…

Discordant Alzheimer's neurodegenerative biomarkers and their clinical outcomes

OBJECTIVE: In the 2018 ATN framework, Alzheimer's neurodegenerative biomarkers comprised cerebrospinal fluid (CSF) total tau, (18)F‐fluorodeoxyglucose‐positron emission tomography, and brain atrophy. We aimed to assess the clinical outcomes of having discordant Alzheimer's neurodegenerativ...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Yu, Li, Hong‐Qi, Tan, Lin, Chen, Shi‐Dong, Yang, Yu‐Xiang, Ma, Ya‐Hui, Zuo, Chuan‐Tao, Dong, Qiang, Tan, Lan, Yu, Jin‐Tai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7545611/
https://www.ncbi.nlm.nih.gov/pubmed/32949193
http://dx.doi.org/10.1002/acn3.51196
_version_ 1783592062832082944
author Guo, Yu
Li, Hong‐Qi
Tan, Lin
Chen, Shi‐Dong
Yang, Yu‐Xiang
Ma, Ya‐Hui
Zuo, Chuan‐Tao
Dong, Qiang
Tan, Lan
Yu, Jin‐Tai
author_facet Guo, Yu
Li, Hong‐Qi
Tan, Lin
Chen, Shi‐Dong
Yang, Yu‐Xiang
Ma, Ya‐Hui
Zuo, Chuan‐Tao
Dong, Qiang
Tan, Lan
Yu, Jin‐Tai
author_sort Guo, Yu
collection PubMed
description OBJECTIVE: In the 2018 ATN framework, Alzheimer's neurodegenerative biomarkers comprised cerebrospinal fluid (CSF) total tau, (18)F‐fluorodeoxyglucose‐positron emission tomography, and brain atrophy. We aimed to assess the clinical outcomes of having discordant Alzheimer's neurodegenerative biomarkers. METHODS: A total of 721 non‐demented individuals from the Alzheimer's Disease Neuroimaging Initiative database were included and then further categorized into concordant‐negative, discordant, and concordant‐positive groups. Demographic distributions of the groups were compared. Longitudinal changes in clinical outcomes and risk of conversion were assessed using linear mixed‐effects models and multivariate Cox proportional hazard models, respectively. RESULTS: Discordant group was intermediate to concordant‐negative and concordant‐positive groups in terms of APOE ε4 positivity, CSF amyloid‐beta, and phosphorylated tau. Compared with concordant‐negative group, discordant group deteriorated faster in cognitive scores (Mini‐Mental State Examination, the Clinical Dementia Rating Scale‐Sum of Boxes, and the Functional Activities Questionnaire) and demonstrated greater rates of atrophy in brain structures (hippocampus, entorhinal cortex, and whole brain), and concordant‐positive group performed worse over time than discordant group. Moreover, the risk of cognitive decline increased from concordant‐negative to discordant to concordant‐positive. The results from longitudinal analyses were validated in A+T+, cognitively normal, and mild cognitive impairment individuals, and were also validated by applying different cutoffs and neurodegenerative biomarkers. INTERPRETATION: Discordant neurodegenerative status denotes a stage of cognitive function which is intermediate between concordant‐negative and concordant‐positive. Identification of discordant cases would provide insights into intervention and new therapy approaches, particularly in A+T+ individuals. Moreover, this work may be a complement to the ATN scheme.
format Online
Article
Text
id pubmed-7545611
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-75456112020-10-16 Discordant Alzheimer's neurodegenerative biomarkers and their clinical outcomes Guo, Yu Li, Hong‐Qi Tan, Lin Chen, Shi‐Dong Yang, Yu‐Xiang Ma, Ya‐Hui Zuo, Chuan‐Tao Dong, Qiang Tan, Lan Yu, Jin‐Tai Ann Clin Transl Neurol Research Articles OBJECTIVE: In the 2018 ATN framework, Alzheimer's neurodegenerative biomarkers comprised cerebrospinal fluid (CSF) total tau, (18)F‐fluorodeoxyglucose‐positron emission tomography, and brain atrophy. We aimed to assess the clinical outcomes of having discordant Alzheimer's neurodegenerative biomarkers. METHODS: A total of 721 non‐demented individuals from the Alzheimer's Disease Neuroimaging Initiative database were included and then further categorized into concordant‐negative, discordant, and concordant‐positive groups. Demographic distributions of the groups were compared. Longitudinal changes in clinical outcomes and risk of conversion were assessed using linear mixed‐effects models and multivariate Cox proportional hazard models, respectively. RESULTS: Discordant group was intermediate to concordant‐negative and concordant‐positive groups in terms of APOE ε4 positivity, CSF amyloid‐beta, and phosphorylated tau. Compared with concordant‐negative group, discordant group deteriorated faster in cognitive scores (Mini‐Mental State Examination, the Clinical Dementia Rating Scale‐Sum of Boxes, and the Functional Activities Questionnaire) and demonstrated greater rates of atrophy in brain structures (hippocampus, entorhinal cortex, and whole brain), and concordant‐positive group performed worse over time than discordant group. Moreover, the risk of cognitive decline increased from concordant‐negative to discordant to concordant‐positive. The results from longitudinal analyses were validated in A+T+, cognitively normal, and mild cognitive impairment individuals, and were also validated by applying different cutoffs and neurodegenerative biomarkers. INTERPRETATION: Discordant neurodegenerative status denotes a stage of cognitive function which is intermediate between concordant‐negative and concordant‐positive. Identification of discordant cases would provide insights into intervention and new therapy approaches, particularly in A+T+ individuals. Moreover, this work may be a complement to the ATN scheme. John Wiley and Sons Inc. 2020-09-19 /pmc/articles/PMC7545611/ /pubmed/32949193 http://dx.doi.org/10.1002/acn3.51196 Text en © 2020 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Research Articles
Guo, Yu
Li, Hong‐Qi
Tan, Lin
Chen, Shi‐Dong
Yang, Yu‐Xiang
Ma, Ya‐Hui
Zuo, Chuan‐Tao
Dong, Qiang
Tan, Lan
Yu, Jin‐Tai
Discordant Alzheimer's neurodegenerative biomarkers and their clinical outcomes
title Discordant Alzheimer's neurodegenerative biomarkers and their clinical outcomes
title_full Discordant Alzheimer's neurodegenerative biomarkers and their clinical outcomes
title_fullStr Discordant Alzheimer's neurodegenerative biomarkers and their clinical outcomes
title_full_unstemmed Discordant Alzheimer's neurodegenerative biomarkers and their clinical outcomes
title_short Discordant Alzheimer's neurodegenerative biomarkers and their clinical outcomes
title_sort discordant alzheimer's neurodegenerative biomarkers and their clinical outcomes
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7545611/
https://www.ncbi.nlm.nih.gov/pubmed/32949193
http://dx.doi.org/10.1002/acn3.51196
work_keys_str_mv AT guoyu discordantalzheimersneurodegenerativebiomarkersandtheirclinicaloutcomes
AT lihongqi discordantalzheimersneurodegenerativebiomarkersandtheirclinicaloutcomes
AT tanlin discordantalzheimersneurodegenerativebiomarkersandtheirclinicaloutcomes
AT chenshidong discordantalzheimersneurodegenerativebiomarkersandtheirclinicaloutcomes
AT yangyuxiang discordantalzheimersneurodegenerativebiomarkersandtheirclinicaloutcomes
AT mayahui discordantalzheimersneurodegenerativebiomarkersandtheirclinicaloutcomes
AT zuochuantao discordantalzheimersneurodegenerativebiomarkersandtheirclinicaloutcomes
AT dongqiang discordantalzheimersneurodegenerativebiomarkersandtheirclinicaloutcomes
AT tanlan discordantalzheimersneurodegenerativebiomarkersandtheirclinicaloutcomes
AT yujintai discordantalzheimersneurodegenerativebiomarkersandtheirclinicaloutcomes
AT discordantalzheimersneurodegenerativebiomarkersandtheirclinicaloutcomes